Last reviewed · How we verify
Cysview
At a glance
| Generic name | Cysview |
|---|---|
| Also known as | Hexyl aminolevulinate (HAL), hexaminolevulinate |
| Sponsor | Johns Hopkins University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Blue Light Cystoscopy With Cysview® Registry
- Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection (PHASE3)
- The Correlation of Surgical Colorectal Cancer Specimen Pathology With the Fluorescence of Photodynamic Diagnostics (PHASE2)
- Longer-term Recurrence Rates in Patients With Bladder Cancer After Hexvix (Cysview)Fluorescence Cystoscopy/TURB
- A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance Setting (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |